Evelo Biosciences, Inc.

EVLO · OTC
Analyze with AI
9/30/2023
6/30/2023
3/31/2023
12/31/2022
Operating Activities
Net Income-$12,364-$21,103-$25,341-$23,541
Dep. & Amort.$169$424$445$523
Deferred Tax$0$1,642$0$0
Stock-Based Comp.$2,476$2,365$2,909$3,421
Change in WC-$3,494-$4,021$1,455-$5,726
Other Non-Cash$2,805$866$256$2,133
Operating Cash Flow-$10,408-$19,827-$20,276-$23,190
Investing Activities
PP&E Inv.-$47$0-$12-$228
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$560-$12$0$0
Investing Cash Flow$513-$12-$12-$228
Financing Activities
Debt Repay.$0$0$0-$3,123
Stock Issued$24,305$0$0$4,862
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$5,085-$199-$199$0
Financing Cash Flow$19,220-$199-$199$1,739
Forex Effect-$49-$18$17$568
Net Chg. in Cash$9,276-$19,845-$20,470-$21,111
Supplemental Information
Beg. Cash$8,783$28,628$49,098$70,209
End Cash$18,059$8,783$28,628$49,098
Free Cash Flow-$10,455-$19,827-$20,288-$23,418